Evogene Partners with Unravel to Develop Innovative MS Remyelination Therapies Using AI

Strategic Partnership Pioneers Remyelination Therapies for Multiple Sclerosis

Evogene Ltd. and Unravel Biosciences, Inc. forge a strategic partnership aimed at developing groundbreaking remyelination therapies for demyelinating diseases, notably Multiple Sclerosis (MS), which currently impacts approximately 3 million individuals worldwide. This collaboration represents a crucial response to a significant medical need, as existing MS treatments primarily focus on slowing disease progression rather than repairing neurological damage. By seeking to create a first-in-class small-molecule therapeutic capable of restoring myelin, the partnership aims to reverse the debilitating effects of demyelination, a condition that severely affects the quality of life for millions.

The integration of Evogene's ChemPass AI technology and Unravel's Predictable Medicine™ platform is a cornerstone of this collaboration. ChemPass AI employs advanced computational chemistry to streamline the drug discovery process, while Predictable Medicine™ utilizes AI-driven predictive biology and patient-derived data to pinpoint novel drug targets. This function-first discovery approach is built on unique biological insights gathered from genetically defined demyelinating disorders, allowing the partnership to develop targeted therapies that effectively address the root causes of myelin damage. The collaboration’s focus on identifying brain-penetrant inhibitors targeting a novel demyelination target underscores its commitment to creating innovative solutions in the neuropharmaceutical landscape.

Moreover, the partnership enhances its research capabilities by integrating advanced RNA-based network simulations and predictive AI modeling, enabling Unravel to generate therapeutic insights that tackle the complexities of restoring neurological function. This synergistic approach combines Evogene's generative AI models, which optimize drug candidates across critical parameters, with Unravel's deep understanding of the biological mechanisms involved in MS. Together, they strive to advance the field of remyelination therapies, potentially leading to significant improvements in treatment efficacy for those suffering from MS and related conditions.

In addition to its innovative therapeutic pursuits, this partnership highlights a growing trend in the biotechnology industry, where AI and computational tools increasingly play a pivotal role in drug discovery. As more companies leverage technology to address unmet medical needs, the collaboration between Evogene and Unravel showcases how strategic alliances can accelerate the development of therapies that have the potential to reshape patient outcomes.

The focus on restoring myelin represents a transformative shift in the management of demyelinating diseases, emphasizing the importance of targeting the underlying causes of neurological damage rather than merely managing symptoms. With millions affected by MS globally, the outcomes of this collaboration could significantly enhance treatment options and improve the lives of patients facing the challenges of these debilitating conditions.